Deep Learning for Automated Elective Lymph Node Level Segmentation for Head and Neck Cancer Radiotherapy.
auto-contouring
computed tomography
deep learning
head-and-neck cancer
lymph nodes
radiation oncology
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Nov 2022
09 Nov 2022
Historique:
received:
30
09
2022
revised:
31
10
2022
accepted:
07
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Depending on the clinical situation, different combinations of lymph node (LN) levels define the elective LN target volume in head-and-neck cancer (HNC) radiotherapy. The accurate auto-contouring of individual LN levels could reduce the burden and variability of manual segmentation and be used regardless of the primary tumor location. We evaluated three deep learning approaches for the segmenting individual LN levels I−V, which were manually contoured on CT scans from 70 HNC patients. The networks were trained and evaluated using five-fold cross-validation and ensemble learning for 60 patients with (1) 3D patch-based UNets, (2) multi-view (MV) voxel classification networks and (3) sequential UNet+MV. The performances were evaluated using Dice similarity coefficients (DSC) for automated and manual segmentations for individual levels, and the planning target volumes were extrapolated from the combined levels I−V and II−IV, both for the cross-validation and for an independent test set of 10 patients. The median DSC were 0.80, 0.66 and 0.82 for UNet, MV and UNet+MV, respectively. Overall, UNet+MV significantly (p < 0.0001) outperformed other arrangements and yielded DSC = 0.87, 0.85, 0.86, 0.82, 0.77, 0.77 for the combined and individual level I−V structures, respectively. Both PTVs were also significantly (p < 0.0001) more accurate with UNet+MV, with DSC = 0.91 and 0.90, respectively. The accurate segmentation of individual LN levels I−V can be achieved using an ensemble of UNets. UNet+MV can further refine this result.
Identifiants
pubmed: 36428593
pii: cancers14225501
doi: 10.3390/cancers14225501
pmc: PMC9688342
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Dutch Cancer Society
ID : 2017.10873
Organisme : Dutch Cancer Society
ID : 2021.13785
Organisme : Varian Medical Systems (United States)
Références
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):677-684
pubmed: 30836167
Med Phys. 2010 Dec;37(12):6338-46
pubmed: 21302791
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):959-66
pubmed: 20231069
Med Phys. 2019 Feb;46(2):576-589
pubmed: 30480818
Radiother Oncol. 2020 Dec;153:180-188
pubmed: 33065182
Radiother Oncol. 2019 Aug;137:9-15
pubmed: 31048235
Radiother Oncol. 2018 Jan;126(1):3-24
pubmed: 29180076
Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):801-812
pubmed: 33068690
Front Oncol. 2017 Dec 20;7:315
pubmed: 29376025
Mult Scler. 2022 Apr;28(4):541-549
pubmed: 34259591
Cancer Imaging. 2022 Jan 15;22(1):8
pubmed: 35033188
Comput Biol Med. 2022 Feb 6;143:105295
pubmed: 35168082
Sci Rep. 2021 Jul 16;11(1):14590
pubmed: 34272413
Med Phys. 2019 Nov;46(11):4763-4776
pubmed: 31132144
BMC Med Imaging. 2012 Jul 19;12:17
pubmed: 22812697
Radiother Oncol. 2014 Jan;110(1):172-81
pubmed: 24183870
Neuroimage. 2019 Aug 1;196:1-15
pubmed: 30953833
Radiat Oncol. 2020 Dec 1;15(1):272
pubmed: 33261620
Med Image Comput Comput Assist Interv. 2014;17(Pt 1):520-7
pubmed: 25333158
Adv Radiat Oncol. 2021 Jan 29;6(2):100658
pubmed: 33778184
Acta Oncol. 2021 Nov;60(11):1399-1406
pubmed: 34264157